

Name of the Issue: Mankind Pharma Limited

- 1 Type of Issue (IPO/FPO)** IPO
- 2 Issue Size (Rs. Cr)** 43,263.55*
* As per Basis of Allotment
- 3 Grade of issue alongwith name of the rating agency**
Name Not Applicable
Grade Not Applicable
- 4 Subscription Level (Number of times):** 15.4631*
* Based on valid applications (excluding Anchor investors, duplicate and multiple bids)
Source: Minutes of Basis of Allotment dated May 03, 2023

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	5.28%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	5.25%
(iii) at the end of 1st FY (March 31, 2023)	5.25%
(iv) at the end of 2nd FY (March 31, 2024)#	Not Available
(v) at the end of 3rd FY (March 31, 2025)#	Not Available

* As per the Basis of Allotment dated May 03, 2023

QIB Holding not disclosed as reporting for relevant period / fiscal years have not been completed/ not publicly available

Source: Basis of allotment, as reported to stock exchanges, BSE and NSE

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

(Rs. Crore)

Parameters (Consolidated)	1st FY (March 31, 2024) ⁽¹⁾	2nd FY (March 31, 2025) ⁽¹⁾	3rd FY (March 31, 2026) ⁽¹⁾
Income from operations	Not Available	Not Available	Not Available
Net Profit for the period	Not Available	Not Available	Not Available
Paid-up equity share capital	Not Available	Not Available	Not Available
Reserves excluding revaluation reserves	Not Available	Not Available	Not Available

⁽¹⁾ Financials not disclosed as reporting for the fiscal year has not been completed/ not publicly available

7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.

The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)*	Not Applicable
(ii) at the end of 2nd FY (March 31, 2025)*	Not Applicable
(iii) at the end of 3rd FY (March 31, 2026)*	Not Applicable

* Trading status not disclosed as the relevant fiscal year has not been completed.

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)*	Not Available	Not Available
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

As per the website of BSE and NSE

* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document - Not applicable as 100% OFS
- (ii) Actual implementation - Not Applicable
- (iii) Reasons for delay in implementation, if any - Not Applicable

10 Status of utilization of issue proceeds

- (i) as disclosed in the offer document - Not applicable as 100% OFS
- (ii) Actual utilization - Not applicable
- (iii) Reasons for deviation, if any - Not Applicable

11 Comments of monitoring agency, if applicable

Not Applicable

12 Pricing Data

Issue Price (Rs.): 1,080
 Designated Stock Exchange: NSE
 Listing Date: 09-May-23

Price parameters	At close of listing day (9-May-2023)	At close of 30th calendar day from listing day ⁽¹⁾	At close of 90th calendar day from listing day ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	1,422.30	1,486.15	1,880.60	N.A	N.A	N.A
Nifty 50	18,265.95	18,726.40	19,517.00	N.A	N.A	N.A
Sectoral Index	N.A.	N.A.	N.A	N.A	N.A	N.A

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2026) ⁽⁴⁾		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	N.A	N.A	N.A	N.A	N.A	N.A
Nifty 50	N.A	N.A	N.A	N.A	N.A	N.A
Sectoral Index	N.A	N.A	N.A	N.A	N.A	N.A

Source: NSE Website

Company is not part of any sectoral index

⁽¹⁾ 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th calendar day is a holiday, in which case we have considered the closing data of the previous trading day

⁽²⁾ 90th calendar day has been taken as listing date plus 89 calendar days, except where 90th calendar day is a holiday, in which case we have considered the closing data of the previous trading day

⁽³⁾ High and Low based on intra day prices

⁽⁴⁾ Pricing data not disclosed as the relevant fiscal year has not been completed

13 Basis for Issue Price

Accounting ratio		As disclosed in the prospectus dated April 28, 2023 ⁽¹⁾	At the end of 1st FY (March 31, 2023)	At the end of 2nd FY (March 31, 2024) ⁽²⁾	At the end of 3rd FY (March 31, 2025) ⁽²⁾
Diluted EPS (Rs.)	Issuer*:	35.78	32.00	Not Available	Not Available
	Peer Group & Industry Average**:	78.00	76.67	Not Applicable	Not Applicable
	Sun Pharmaceuticals Industries Limited	13.60	35.30	Not Applicable	Not Applicable
	Cipla Limited	31.17	34.69	Not Applicable	Not Applicable
	Zydus Lifesciences Limited	43.83	19.30	Not Applicable	Not Applicable
	Torrent Pharmaceutical Limited	22.97	36.79	Not Applicable	Not Applicable
	Alkem Laboratories ⁽³⁾	137.63	85.37	Not Applicable	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	49.82	52.34	Not Applicable	Not Applicable
	Eris Lifesciences Limited	29.88	28.07	Not Applicable	Not Applicable
	Ipca Laboratories Limited	34.85	18.58	Not Applicable	Not Applicable
	Abbott India Limited	375.86	446.78	Not Applicable	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	100.04	36.05	Not Applicable	Not Applicable
	Dabur India Limited	9.81	9.61	Not Applicable	Not Applicable
	Procter & Gamble Health Limited	116.00	145.10	Not Applicable	Not Applicable
	Zydus Wellness Limited	48.54	48.78	Not Applicable	Not Applicable
P/E(x)	Issuer*:	30.18***	33.75***	Not Available	Not Available
	Peer Group & Industry Average**:	40.16	35.19	Not Applicable	Not Applicable
	Sun Pharmaceuticals Industries Limited	71.54	27.85	Not Applicable	Not Applicable
	Cipla Limited	28.18	25.94	Not Applicable	Not Applicable
	Zydus Lifesciences Limited	10.95	25.47	Not Applicable	Not Applicable
	Torrent Pharmaceutical Limited	66.25	41.79	Not Applicable	Not Applicable
	Alkem Laboratories ⁽³⁾	23.03	24.69	Not Applicable	Not Applicable

JB Chemicals & Pharmaceuticals Limited	39.48	37.19	Not Applicable	Not Applicable
Eris Lifesciences Limited	19.10	20.36	Not Applicable	Not Applicable
Ipca Laboratories Limited	22.38	43.61	Not Applicable	Not Applicable
Abbott India Limited	56.19	49.43	Not Applicable	Not Applicable
Glaxosmithkline Pharmaceuticals Limited	57.03	36.73	Not Applicable	Not Applicable
Dabur India Limited	54.55	56.55	Not Applicable	Not Applicable
Procter & Gamble Health Limited	42.27	36.10	Not Applicable	Not Applicable
Zydus Wellness Limited	31.11	31.77	Not Applicable	Not Applicable

RoNW (%) **Issuer*:** 23.29 N/A Not Available Not Available

Peer Group & Industry Average**:	21.78	19.05	Not Applicable	Not Applicable
Sun Pharmaceuticals Industries Limited	6.82	N/A	Not Applicable	Not Applicable
Cipla Limited	12.08	N/A	Not Applicable	Not Applicable
Zydus Lifesciences Limited	26.40	N/A	Not Applicable	Not Applicable
Torrent Pharmaceutical Limited	13.06	N/A	Not Applicable	Not Applicable
Alkem Laboratories ⁽³⁾	19.05	19.05	Not Applicable	Not Applicable
JB Chemicals & Pharmaceuticals Limited	18.06	N/A	Not Applicable	Not Applicable
Eris Lifesciences Limited	21.28	N/A	Not Applicable	Not Applicable
Ipca Laboratories Limited	16.10	N/A	Not Applicable	Not Applicable
Abbott India Limited	28.32	N/A	Not Applicable	Not Applicable
Glaxosmithkline Pharmaceuticals Limited	63.64	N/A	Not Applicable	Not Applicable
Dabur India Limited	20.75	N/A	Not Applicable	Not Applicable
Procter & Gamble Health Limited ⁽⁴⁾	31.23	N/A	Not Applicable	Not Applicable
Zydus Wellness Limited	6.38	N/A	Not Applicable	Not Applicable

NAV per share based on last balance sheet **Issuer*:** 153.65 N/A Not Available Not Available

Peer Group & Industry Average**:	368.06	722.44	Not Applicable	Not Applicable
Sun Pharmaceuticals Industries Limited	200.10	N/A	Not Applicable	Not Applicable
Cipla Limited	258.32	N/A	Not Applicable	Not Applicable
Zydus Lifesciences Limited	166.05	N/A	Not Applicable	Not Applicable
Torrent Pharmaceutical Limited	175.89	N/A	Not Applicable	Not Applicable
Alkem Laboratories ⁽³⁾	722.44	722.44	Not Applicable	Not Applicable

JB Chemicals & Pharmaceuticals Limited	240.83	N/A	Not Applicable	Not Applicable
Eris Lifesciences Limited	140.39	N/A	Not Applicable	Not Applicable
Ipca Laboratories Limited	216.47	N/A	Not Applicable	Not Applicable
Abbott India Limited	1,327.00	N/A	Not Applicable	Not Applicable
Glaxosmithkline Pharmaceuticals Limited	157.19	N/A	Not Applicable	Not Applicable
Dabur India Limited	47.41	N/A	Not Applicable	Not Applicable
Procter & Gamble Health Limited ⁽⁴⁾	371.39	N/A	Not Applicable	Not Applicable
Zydus Wellness Limited	761.26	N/A	Not Applicable	Not Applicable

Source:

* All the financial information for the Company above is on a restated and consolidated basis.

** All the financial information for listed industry peers mentioned above is on a consolidated basis (unless otherwise available only on standalone basis) and is sourced from the financial statements of the respective company for the fiscal year ended March 31

*** P/E Ratio for the Company has been computed based on the Offer Price of ₹ 1,080 per Equity Share divided by the Diluted EPS as at March 31, 2022.

Notes:

⁽¹⁾ Sourced from Prospectus dated April 28, 2023.

⁽²⁾ Information not provided as the relevant fiscal year has not completed or data not available

⁽³⁾ For Alkem Laboratories, the latest financials are as of December 31, 2022.

Accordingly, Diluted EPS, RoNW and NAV pertain to year ended December 31, 2022

⁽⁴⁾ For Procter & Gamble Health Limited the latest B/S is for the year ended December 31, 2022.

Accordingly, RoNW and NAV pertain to year ended December 31, 2022

14 Any other material information

Particulars	Date
Change in Senior Management Personnel	16-Oct-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Para A of Part A of Schedule III to the Listing Regulations, Company informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company vide Circular Resolution passed on 16th October 2023, approved the appointment of Mr. Prateek Dubey as President – Global Chief Human Resource Officer (being Senior Management Personnel) w.e.f. October 16, 2023	
Intimation of resumption of operations at the Company's manufacturing facility at Sikkim	13-Oct-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Para B of Part A of Schedule III to the Listing Regulations and in continuation to Company's letter dated October 5, 2023 regarding disruptions of operations at the Company's manufacturing facility at Daring Block, Berimok, Namchi Zilla, South Sikkim ("Sikkim manufacturing facility") due to disturbance in power/utility supply because of flash floods. Company informed that Sikkim manufacturing facility has resumed its operations as usual with effect from October 13, 2023	
Intimation of Commencement of Commercial Operations at Udaipur Plant	25-Sep-23
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Para B of Part A of Schedule III to the Listing Regulations, Company informed that the commercial operations with respect to pharmaceutical formulations has commenced at the Company's newly set-up plant in Udaipur, Rajasthan with effect from today i.e. September 25, 2023	

<p>Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Listing Regulations")</p> <p>Income Tax Department ("IT Dept") conducted search under the Income Tax Act, 1961 at some of the offices and plants of the Company and its subsidiaries. The company cooperated with the officials of IT Dept during the proceedings and responded to the clarifications and details sought by them. The business operations of the Company continue as usual and have not been impacted due to the search</p>	17-May-23
<p>Change in Director: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ("the Listing Regulations")</p> <p>Mr. Leonard Lee (DIN: 07379167) a director representing CIPEF and CGPE on the Board of Directors of the Company has tendered his resignation with effect from 9th May 2023</p>	09-May-23
<p>Listing of equity shares of Mankind Pharma Limited</p> <p><i>Source: Stock Exchange filings; For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com</i></p>	09-May-23